Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
20 hedge funds and large institutions have $22.9M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
5% less funds holding
Funds holding: 21 → 20 (-1)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
43% less capital invested
Capital invested by funds: $40.1M → $22.9M (-$17.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$783K |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$44.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.63K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$294 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$724K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$163K |
| 3 |
B
Bailard
Foster City,
California
|
-$110K |
| 4 |
V
Veritable
Wilmington,
Delaware
|
-$110K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$53.1K |
LBPH Hedge Fund Activity: Q2 2022 in Review
20 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q2 2022, worth a combined $22.9M — down 43% from $40.1M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LBPH and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 5 added.
The largest buyer was Citigroup, adding an estimated $783K. The largest seller was Fidelity Investments, cutting an estimated $724K.
- 20 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q2 2022, down from 21 in Q1 2022.
- Funds reported $22.9M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 43% quarter-over-quarter.
- 2 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 3 closed out, a net change of -1 holder.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Citigroup, an estimated $783K added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Fidelity Investments, an estimated $724K sold.
Based on aggregated 13F filings for Q2 2022.